Scientists use insurance data to forecast major drug trial outcome
NCT ID NCT07088718
Summary
This study aimed to predict the results of a major heart drug trial before it finishes. Researchers analyzed health insurance records from over 44,000 people with type 2 diabetes and heart disease to see if one diabetes drug (tirzepatide) is better than another (dulaglutide) at preventing heart attacks, strokes, or death. The goal was to test how well real-world health data can be used to forecast the results of carefully controlled clinical trials.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETES are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.